Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 20/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7520576 | 0.91 | GNRHR (0.58) | GNRHRMEN1KMT2A | |
| SCHEMBL7518445 | 0.90 | GNRHR (0.53) | GNRHRMEN1KMT2A | |
| SCHEMBL8160095 | 0.89 | GNRHR (0.53) | GNRHRMEN1KMT2A | |
| SCHEMBL7525348 | 0.89 | GNRHR (0.64) | GNRHRMEN1KMT2A | |
| SCHEMBL7521064 | 0.89 | GNRHR (0.73) | GNRHRMEN1KMT2A | |
| SCHEMBL7498273 | 0.86 | GNRHR (0.67) | GNRHR | |
| SCHEMBL7011239 | 0.84 | GNRHR (0.84) | GNRHRMEN1KMT2A | |
| SCHEMBL8165422 | 0.82 | GNRHR (0.49) | GNRHRMEN1KMT2A | |
| SCHEMBL8160020 | 0.82 | GNRHR (0.43) | GNRHRMEN1KMT2A | |
| SCHEMBL8166111 | 0.81 | GNRHR (0.42) | GNRHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198384-A1 | Thienopyridine derivatives, their intermediates and production thereof | MIKI SHOKYO (JP) | 2002-12-26 | — | — | US | claimed |
| US-20020019529-A1 | Thienopyridine derivatives, their intermediates and production thereof | MIKI SHOKYO (JP) | 2002-02-14 | — | — | US | claimed |
| EP-1004585-A1 | THIENOPYRIDINE DERIVATIVES, INTERMEDIATES THEREOF, AND PROCESS FOR PRODUCING THE BOTH | Takeda Chemical Industries, Ltd. (JP) | 2000-05-31 | — | — | EP | claimed |
| US-20020198384-A1 | Thienopyridine derivatives, their intermediates and production thereof | MIKI SHOKYO (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6437132-B2 | INHIBITOR OF GONADOTROPIN RELEASING HORMONE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-08-20 | — | — | US | disclosed |
| US-20020019529-A1 | Thienopyridine derivatives, their intermediates and production thereof | MIKI SHOKYO (JP) | 2002-02-14 | — | — | US | disclosed |
| US-6329388-B2 | GONADOTROPIN-RELEASING HORMONE ANTAGONIZING ACTIVITY; USEFUL FOR PREVENTING OR TREATING SEX HORMONE-DEPENDENT DISEASES, E.G., SEX HORMONE-DEPENDENT CANCERS (E.G., PROSTATIC CANCER, UTERINE CANCER, BREAST CANCER, PITUITARY TUMOR) | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-12-11 | — | — | US | disclosed |
| US-6313301-B1 | CYCLIZATION; LUTEINIZING HORMONE RELEASING HORMONE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-11-06 | — | — | US | disclosed |
| US-6297255-B1 | GONADOTROPIN-RELEASING HORMONE ANTAGONIZING ACTIVITY; PREVENTING OR TREATING SEX HORMONE-DEPENDENT DISEASES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-02 | — | — | US | disclosed |
| US-6262267-B1 | HAS GONADOTROPIN-RELEASING HORMONE ANTAGONIZING ACTIVITY; USEFUL FOR PREVENTING OR TREATING SEX HORMONE-DEPENDENT DISEASES, E,G., SEX HORMONE-DEPENDENT CANCERS E.G., PROSTATIC CANCER, UTERINE CANCER, BREAST CANCER, PITUITARY TUMOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-07-17 | — | — | US | disclosed |
| US-20010001104-A1 | Thienopyridine compounds, their production and use | FURUYA SHUICHI (JP) | 2001-05-10 | — | — | US | disclosed |
| EP-1004585-A1 | THIENOPYRIDINE DERIVATIVES, INTERMEDIATES THEREOF, AND PROCESS FOR PRODUCING THE BOTH | Takeda Chemical Industries, Ltd. (JP) | 2000-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198384-A1 | Thienopyridine derivatives, their intermediates and production thereof | GNRHR, KISS1R, CYP19A1 | GNRHR 1/4885MEN1 1739/4885KMT2A 1900/4885 |
| US-20010001104-A1 | Thienopyridine compounds, their production and use | PRLHR, PGR, GNRHR | GNRHR 3/4885MEN1 517/4885KMT2A 446/4885 |
| US-20020019529-A1 | Thienopyridine derivatives, their intermediates and production thereof | GNRHR, KISS1R, CYP19A1 | GNRHR 1/4885MEN1 1739/4885KMT2A 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.